A carregar...
Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab
BACKGROUND: Current therapy for allergic bronchopulmonary aspergillosis (ABPA) uses oral corticosteroids, exposing patients to the adverse effects of these agents. There are reports of the steroid-sparing effect of anti-IgE therapy with omalizumab for ABPA in patients with cystic fibrosis (CF), but...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3508546/ https://ncbi.nlm.nih.gov/pubmed/23204847 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S34579 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|